(Q33813448)

29 July 2017

title

Comparison of error rates in single-arm versus randomized phase II cancer clinical trials (English)

1 reference

29 July 2017

main subject

phase II clinical trial

0 references

Daniel J Sargent

6

1 reference

ORCID Public Data File 2021

author name string

Hui Tang

1

1 reference

29 July 2017

Nathan R Foster

2

1 reference

29 July 2017

Axel Grothey

3

1 reference

29 July 2017

Stephen M Ansell

4

1 reference

29 July 2017

Richard M Goldberg

5

1 reference

29 July 2017

language of work or name

English

0 references

publication date

8 March 2010

1 reference

Journal of Clinical Oncology

29 July 2017

published in

1 reference

29 July 2017

volume

28

1 reference

29 July 2017

issue

11

1 reference

29 July 2017

page(s)

1936-1941

1 reference

Randomized phase II designs.

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860370

Effective incorporation of biomarkers into phase II trials

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860370

Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860370

Speeding up the evaluation of new agents in cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860370

Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860370

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860370

Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860370

Design issues of randomized phase II trials and a proposal for phase II screening trials

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860370

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860370

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860370

When should randomisation begin?

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860370

Optimal two-stage designs for phase II clinical trials

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860370

Incorporating historical control data in planning phase II clinical trials

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860370

Planned versus attained design in phase II clinical trials

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860370

Optimising the design of phase II oncology trials: the importance of randomisation.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860370

Analysis of phase II studies on targeted agents and subsequent phase III trials: what are the predictors for success?

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860370

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860370

One- and two-stage designs for stratified phase II clinical trials

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860370

New designs for phase 2 clinical trials

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860370

A standardization method to adjust for the effect of patient selection in phase II clinical trials.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860370

Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design

30 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20212253

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The phase II/III transition. Toward the proof of efficacy in cancer clinical trials

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20212253

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1200/JCO.2009.25.5489

1 reference

29 July 2017

1 reference

29 July 2017

1 reference